Coherus BioSciences, Inc (CHRS) saw its loss widen to $74.78 million, or $1.54 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $65.39 million, or $1.67 a share. Revenue during the quarter plunged 98.70 percent to $0.16 million from $12.36 million in the previous year period.
Operating loss for the quarter was $72.42 million, compared with an operating loss of $64.35 million in the previous year period.
Debt moves up marginally Coherus BioSciences, Inc has witnessed an increase in total debt over the last one year. It stood at $75.44 million as on Mar. 31, 2017, up 1.27 percent or $0.94 million from $74.49 million on Mar. 31, 2016. Total debt was 33.16 percent of total assets as on Mar. 31, 2017, compared with 32.93 percent on Mar. 31, 2016. Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]